
Juan Carlos Carril

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3908354/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Personalized Management and Treatment of Alzheimer's Disease. Life, 2022, 12, 460.	1.1	4
2	Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease. Pharmaceuticals, 2021, 14, 366.	1.7	6
3	Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Medicinal Research Reviews, 2021, 41, 2841-2886.	5.0	7
4	Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. Drug Development Research, 2021, 82, 695-706.	1.4	3
5	Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. International Journal of Molecular Sciences, 2021, 22, 13302.	1.8	25
6	DNA Methylation in Neurodegenerative and Cerebrovascular Disorders. International Journal of Molecular Sciences, 2020, 21, 2220.	1.8	44
7	Genomics and Pharmacogenomics of Rhinosinusitis. Current Pharmacogenomics and Personalized Medicine, 2020, 17, 114-124.	0.2	0
8	The Epigenetic Machinery in the Life Cycle and Pharmacoepigenetics. , 2019, , 1-100.		9
9	Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics. International Journal of Molecular Sciences, 2019, 20, 1249.	1.8	64
10	The role of pharmacogenomics in adverse drug reactions. Expert Review of Clinical Pharmacology, 2019, 12, 407-442.	1.3	71
11	Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease. Journal of Personalized Medicine, 2018, 8, 3.	1.1	28
12	Pharmacogenetics of Neurodegenerative disorders. Internal Medicine Review (Washington, D C:) Tj ETQq0 0 0 r	gBT/Qverl	ock 10 Tf 50 3
13	Optimization of Antidepressant Use with Pharmacogenetic Strategies. Current Genomics, 2017, 18, 442-449.	0.7	23
14	Pharmacogenetic considerations in the treatment of Alzheimer's disease. Pharmacogenomics, 2016, 17, 1041-1074.	0.6	39
15	Can cloud-based tools accelerate Alzheimer's disease drug discovery?. Expert Opinion on Drug Discovery, 2016, 11, 215-223.	2.5	21
16	Novel Therapeutic Strategies for Dementia. CNS and Neurological Disorders - Drug Targets, 2016, 15, 141-241.	0.8	42
17	Pharmacogenomics of Alzheimer's Disease: Novel Therapeutic Strategies for Drug Development. Methods in Molecular Biology, 2014, 1175, 323-556.	0.4	60

¹⁸ Genomics and Pharmacogenomics of Brain Disorders. Current Pharmaceutical Biotechnology, 2012, 13, 0.9 32 674-725.

#	Article	IF	CITATIONS
19	Genomics of Dementia:APOE- andCYP2D6-Related Pharmacogenetics. International Journal of Alzheimer's Disease, 2012, 2012, 1-37.	1.1	44
20	Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals, 2010, 3, 3040-3100.	1.7	37